The Scottish Medicines Consortium (SMC) has approved Mavenclad (cladribine) as a treatment for highly active relapsing multiple sclerosis.
The government has announced a review of all 1.6 million personal independence payment (PIP) claims following a High Court ruling.
The MS Trust is dismayed by NICE's recommendation. We do not believe it is in the best interests of people with MS or the NHS.
Medday, the company developing high dose biotin for progressive MS, has told the European Medicines Agency that it wishes to withdraw its licence application.
The European Medicines Agency recommends licensing for ocrelizumab (Ocrevus) for treating active relapsing and early primary progressive MS.
NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately.
Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales.